Your browser is out-of-date!

Update your browser to view this website correctly.

1Cookies

2Disclaimer

Biohaven

Key Facts as at 30.09.2025

Company locationUSA
Size in % of securities1.50%
Size of stake in company2.60%
Market capitalizationUSD 1.6 bn

Sector

Autoimmune Disease and CNS

Main candidate

BHVN-1300/1310 and BHVN-7000/7010

Main indications

Myasthenia gravis, rheumatoid arthritis and epilepsy

About the company

Biohaven is a biotechnology company focused on developing new drugs for a broad range of diseases with a focus on immunology and CNS. The company was founded in 2013 but was relaunched in 2022 following Pfizer´s acquisition of the GCRP portfolio for USD 11.6 billion. Biohaven is headquartered in Connecticut in the US. Biohaven has a pipeline of products in preclinical and clinical development for a broad range of disease areas. The company is developing an extracellular protein degradation platform aiming at leveraging the liver to degrade pathogenic extracellular proteins with implications across multiple autoimmune and cardiac diseases. Furthermore the company is exploring a novel mode of action to treat focal epilepsy by activating a specific potassium channel (Kv7). BHV-7000 is currently starting  Phase 2/3 clinical development.

Disclaimer

All comments as at December 31, 2024 or beginning of investment.

Any reference to a particular company or security does not constitute a recommendation to buy, sell, hold or directly invest in that company or security.